Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feng Lei

Showing results (681-690 of 690) with videos related to

Pageof 69
Sort By:
You have reached the last page of results.This site can display upto 690 results.
Cell Reports. Medicine|February 12, 2025
Advanced image-identified extranodal extension of retropharyngeal lymph nodes in the refinement of N classification for nasopharyngeal carcinomaWei Jiang, Gao-Yuan Wang, Guan-Jie Qin, et al.
American Journal of Human Genetics|November 11, 2008
Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosisTie-Lin Yang, Xiang-Ding Chen, Yan Guo, et al.
Lancet (London, England)|October 22, 2025
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in ChinaYunpeng Yang, Huaqiang Zhou, Linquan Tang, et al.
The Lancet. Oncology|June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialYunpeng Yang, Song Qu, Jingao Li, et al.
Plos Genetics|January 15, 2010
Genome-wide association study identifies ALDH7A1 as a novel susceptibility gene for osteoporosisYan Guo, Li-Jun Tan, Shu-Feng Lei, et al.
American Journal of Human Genetics|March 3, 2009
Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groupsDong-Hai Xiong, Xiao-Gang Liu, Yan-Fang Guo, et al.
BMJ (Clinical Research Ed.)|February 10, 2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trialRui You, Gui-Qiong Xu, Xi Ding, et al.
JAMA Oncology|January 29, 2026
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical TrialYan Huang, Dongchen Sun, Huaqiang Zhou, et al.
Cancer Cell|January 19, 2024
Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinomaXiao-Jing Du, Gao-Yuan Wang, Xiao-Dong Zhu, et al.
Neuroimage|June 4, 2013
The CONNECT project: Combining macro- and micro-structureYaniv Assaf, Daniel C Alexander, Derek K Jones, et al.
Pageof 69

Showing results (681-690 of 690) with videos related to

Sort By:
Pageof 69
You have reached the last page of results.This site can display upto 690 results.
Cell Reports. Medicine|February 12, 2025
Advanced image-identified extranodal extension of retropharyngeal lymph nodes in the refinement of N classification for nasopharyngeal carcinomaWei Jiang, Gao-Yuan Wang, Guan-Jie Qin, et al.
American Journal of Human Genetics|November 11, 2008
Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosisTie-Lin Yang, Xiang-Ding Chen, Yan Guo, et al.
Lancet (London, England)|October 22, 2025
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in ChinaYunpeng Yang, Huaqiang Zhou, Linquan Tang, et al.
The Lancet. Oncology|June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialYunpeng Yang, Song Qu, Jingao Li, et al.
Plos Genetics|January 15, 2010
Genome-wide association study identifies ALDH7A1 as a novel susceptibility gene for osteoporosisYan Guo, Li-Jun Tan, Shu-Feng Lei, et al.
American Journal of Human Genetics|March 3, 2009
Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groupsDong-Hai Xiong, Xiao-Gang Liu, Yan-Fang Guo, et al.
BMJ (Clinical Research Ed.)|February 10, 2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trialRui You, Gui-Qiong Xu, Xi Ding, et al.
JAMA Oncology|January 29, 2026
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical TrialYan Huang, Dongchen Sun, Huaqiang Zhou, et al.
Cancer Cell|January 19, 2024
Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinomaXiao-Jing Du, Gao-Yuan Wang, Xiao-Dong Zhu, et al.
Neuroimage|June 4, 2013
The CONNECT project: Combining macro- and micro-structureYaniv Assaf, Daniel C Alexander, Derek K Jones, et al.
Pageof 69